Daewon Pharmaceutical Co. Ltd. (003220) — Capital Reinvestment Ratio

Latest as of March 2026: 1.22x

Daewon Pharmaceutical Co. Ltd. (003220) has a Capital Reinvestment Ratio of 1.22x as of March 2026, meaning it reinvests 1% of its operating cash flow (₩9.21 Billion) in capital expenditures (₩11.26 Billion). See 003220 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Capital Reinvestment Ratio

1.22x
Capex / Operating Cash Flow

Operating Cash Flow

₩9.21 Billion
KRW

Capital Expenditures

₩11.26 Billion
KRW

Data as of

Mar 2026
Most recent filing

Daewon Pharmaceutical Co. Ltd. Capital Reinvestment Ratio (2011–2025)

This chart tracks Daewon Pharmaceutical Co. Ltd.'s Capital Reinvestment Ratio across 15 annual periods. See 003220 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.

Annual Capital Reinvestment Ratio for Daewon Pharmaceutical Co. Ltd. (2011–2025)

Year-by-year Capital Reinvestment Ratio for Daewon Pharmaceutical Co. Ltd. from 2011 to 2025. For the full cash flow conversion analysis, see cash flow conversion of Daewon Pharmaceutical Co. Ltd..

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2025 1.00x ₩42.31 Billion ₩42.13 Billion ▼ -44.2%
2024 1.78x ₩30.04 Billion ₩53.58 Billion ▲ +347.8%
2023 0.40x ₩51.73 Billion ₩20.61 Billion ▼ -0.7%
2022 0.40x ₩33.33 Billion ₩13.37 Billion ▲ +119.0%
2021 0.18x ₩22.41 Billion ₩4.10 Billion ▼ -59.7%
2020 0.45x ₩24.95 Billion ₩11.35 Billion ▼ -57.4%
2019 1.07x ₩30.97 Billion ₩33.03 Billion ▲ +4.6%
2018 1.02x ₩40.03 Billion ₩40.82 Billion ▼ -70.4%
2017 3.45x ₩4.27 Billion ₩14.71 Billion ▲ +248.6%
2016 0.99x ₩20.79 Billion ₩20.57 Billion ▲ +29.0%
2015 0.77x ₩25.82 Billion ₩19.80 Billion ▼ -15.5%
2014 0.91x ₩17.45 Billion ₩15.84 Billion ▲ +13.6%
2013 0.80x ₩12.32 Billion ₩9.85 Billion ▲ +234.6%
2012 0.24x ₩13.83 Billion ₩3.30 Billion ▼ -58.0%
2011 0.57x ₩17.93 Billion ₩10.19 Billion —
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow